Hispanopedia Wiki
Articulo de referencia

CPP-115

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction, [ 1 ] infantile spasms, [ 2 ] [ 3 ...

Hispanopedia WikiContenido en espanolLectura gratuita

CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2][3] and Tourette syndrome.[4]

CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]

History

CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6][7]

CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]

As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]

See also

References

  1. 12Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, et al. (January 2012). "(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction". Journal of Medicinal Chemistry. 55 (1): 357–366. doi:10.1021/jm201231w. PMC 3257419. PMID 22128851.
  2. ↑"Epilepsy Pipeline Tracker: CPP-115". epilepsy.com.
  3. ↑Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O (2016). "A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms". Epilepsy & Behavior Case Reports. 6: 67–69. doi:10.1016/j.ebcr.2016.08.002. PMC 5024311. PMID 27668180.
  4. 12"CPP-115". Adis Insight.
  5. ↑ Silverman RB (enero de 2012). "El premio EB Hershberg 2011 por descubrimientos importantes en sustancias medicinalmente activas: ácido (1S,3S)-3-amino-4-difluorometilenil-1-ciclopentanoico (CPP-115), un inactivador de la GABA aminotransferasa y nuevo tratamiento para la adicción a las drogas y los espasmos infantiles" . Journal of Medicinal Chemistry . 55 (2): 567– 575. doi : 10.1021/jm201650r . PMC 3266980. PMID 22168767 .  
  6. ↑ Hawker DD, Silverman RB (octubre de 2012). " Síntesis y evaluación de nuevos sustratos heteroaromáticos de la GABA aminotransferasa" . Bioorganic & Medicinal Chemistry . 20 (19): 5763– 5773. doi : 10.1016/j.bmc.2012.08.009 . PMC 3448830. PMID 22944334 .  
  7. ↑ Bandell B (31 de agosto de 2009). "Catalyst Pharmaceutical firma un acuerdo de licencia con Northwestern" . South Florida Business Journal.
  8. ↑ "Catalyst Pharmaceuticals amplía su equipo directivo comercial" (Comunicado de prensa). Catalyst Pharmaceuticals.